# Tdap and Biomarkers of Alzheimer's Disease

> **NCT05183516** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mindful Diagnostics and Therapeutics, LLC** · enrollment: 50 (estimated)

## Conditions studied

- Alzheimer Disease, Late Onset

## Interventions

- **BIOLOGICAL:** tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine

## Key facts

- **NCT ID:** NCT05183516
- **Lead sponsor:** Mindful Diagnostics and Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183516, "Tdap and Biomarkers of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05183516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*